A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Brains were extracted and postfixed in 4% PFA overnight at 4 C
doi: 10.1007/s11325-023-02899-w, 9
Focus on: Protein-rich foods at each meal (lean meats, fish, eggs, legumes, dairy) to preserve muscle mass during weight loss High-fibre vegetables and whole grains to support digestive health and provide sustained energy Adequate hydration aim for 6-8 glasses of fluid daily, as recommended by the NHS (individualised advice may apply if you have heart or kidney conditions) Smaller, more frequent meals if large portions trigger nausea Limiting ultra-processed foods, added sugars, and excessive saturated fats The NHS Eatwell Guide provides an excellent framework for balanced nutrition whilst taking GLP-1 medications
2024;196(43):E1413
.jpg)
